Statement by Global Alzheimer’s Platform Foundation® President John Dwyer:
Washington, D.C. (Feb. 27, 2023) — “On behalf of the of the thousands of trial participants, clinicians and researchers who are part of the Global Alzheimer’s Platform Foundation (GAP) network, we want to thank and honor Dr. Billy Dunn for his leadership and scientific contributions, which have made therapies available to patients and families living with Alzheimer’s.
His service at the U.S. Food and Drug Administration, his leadership as the head of the FDA’s neuroscience office and his strategic insights into how to move drugs forward — while safeguarding the patients who take them — is unparalleled. We congratulate Dr. Dunn on his nearly 30 decades of service which has, at times, meant the difference between life and death for people living with neurodegenerative diseases. We are eager to see how the next chapter of Dr. Dunn’s career unfolds in the service of Alzheimer patients.”
For immediate release:
About the Global Alzheimer’s Platform Foundation (GAP)
The nonprofit Global Alzheimer’s Platform Foundation® was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites around the world through study start up and recruitment activities, promoting diversity in research studies, and recognizing the citizen scientists who make research possible.